Showing results (71-80 of 161) with videos related to
Sort By:
Pageof 17
Acta Neuropathologica|September 8, 2022
Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificitiesNatalie Rose, Sebastian Holdermann, Ilaria Callegari, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|September 16, 2017
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosisLudwig Kappos, Douglas L Arnold, Amit Bar-Or, et al.Journal of Neuroinflammation|December 20, 2015
Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluidManfred Wuhrer, Maurice H J Selman, Liam A McDonnell, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|May 29, 2020
Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetateViktor von Wyl, Pascal Benkert, André Moser, et al.The Lancet. Neurology|August 21, 2016
Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trialLudwig Kappos, Douglas L Arnold, Amit Bar-Or, et al.Plos One|January 28, 2014
Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosisKatrin Weier, Iris K Penner, Stefano Magon, et al.European Neurology|January 4, 2019
Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple SclerosisEsther Ruberte, Tim Sinnecker, Michael Amann, et al.JAMA Neurology|October 2, 2023
Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic ReviewJannis Müller, Alessandro Cagol, Johannes Lorscheider, et al.Journal of Neurology|October 9, 2021
Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosisMassimo Filippi, Romano Danesi, Tobias Derfuss, et al.JAMA Neurology|January 8, 2019
Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple SclerosisYvonne Naegelin, Peter Naegelin, Stefanie von Felten, et al.Pageof 17